In AML, the post-translational modifications of NPM1 affect the therapeutic response and SENP3-mediated deSUMOylation of NPM1 induces the resistance of AML cells to chemo- and radiotherapy [36]. The gene discussed is NPM1; the disease is acute myeloid leukemia.